+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

      Cancer research

      Adenocarcinoma, Clear Cell, enzymology, genetics, Carcinoma, Renal Cell, Cell Line, Tumor, Chromosomes, Human, Pair 3, Comparative Genomic Hybridization, DNA Methylation, DNA Mutational Analysis, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Histone-Lysine N-Methyltransferase, Humans, Kidney Neoplasms, Oligonucleotide Array Sequence Analysis, RNA, Messenger, metabolism

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Sporadic clear cell renal cell carcinoma (cRCC) is genetically characterized by the recurrent loss of the short arm of chromosome 3, with a hotspot for copy number loss in the 3p21 region. We applied a method called "gene identification by nonsense-mediated mRNA decay inhibition" to a panel of 10 cRCC cell lines with 3p21 copy number loss to identify biallelic inactivated genes located at 3p21. This revealed inactivation of the histone methyltransferase gene SETD2, located on 3p21.31, as a common event in cRCC cells. SETD2 is nonredundantly responsible for trimethylation of the histone mark H3K36. Consistent with this function, we observed loss or a decrease of H3K36me3 in 7 out of the 10 cRCC cell lines. Identification of missense mutations in 2 out of 10 primary cRCC tumor samples added support to the involvement of loss of SETD2 function in the development of cRCC tumors. Copyright 2010 AACR.

          Related collections

          Author and article information



          Comment on this article